Reactive astrocytes as therapeutic targets for CNS disorders
نویسندگان
چکیده
منابع مشابه
L-type calcium channels as drug targets in CNS disorders
L-type calcium channels are present in most electrically excitable cells and are needed for proper brain, muscle, endocrine and sensory function. There is accumulating evidence for their involvement in brain diseases such as Parkinson disease, febrile seizures and neuropsychiatric disorders. Pharmacological inhibition of brain L-type channel isoforms, Cav1.2 and Cav1.3, may therefore be of ther...
متن کاملPhytocannabinoids as novel therapeutic agents in CNS disorders.
The Cannabis sativa herb contains over 100 phytocannabinoid (pCB) compounds and has been used for thousands of years for both recreational and medicinal purposes. In the past two decades, characterisation of the body's endogenous cannabinoid (CB) (endocannabinoid, eCB) system (ECS) has highlighted activation of central CB(1) receptors by the major pCB, Δ(9)-tetrahydrocannabinol (Δ(9)-THC) as th...
متن کاملAstrocytes as new targets for antiepileptic drugs
Epilepsy is a disorder of the brain characterised by un-provoked, recurrent seizures and affects about 1% of the population worldwide. A deeper understanding of the cellular basis of the epilepsies would be essential for the identification of novel targets for therapeutic intervention. Since neuronal hyperexcitation and hypersynchronization are hallmarks of epilepsy, the search for new antiepil...
متن کاملReactive oxygen species as therapeutic targets in pulmonary hypertension.
Pulmonary hypertension (PH) is characterized by a progressive elevation of pulmonary arterial pressure due to alterations of both pulmonary vascular structure and function. This disease is rare but life-threatening, leading to the development of right heart failure. Current PH treatments, designed to target altered pulmonary vascular reactivity, include vasodilating prostanoids, phosphodiestera...
متن کاملNew therapeutic targets for mood disorders.
Existing pharmacological treatments for bipolar disorder (BPD) and major depressive disorder (MDD) are often insufficient for many patients. Here we describe a number of targets/compounds that clinical and preclinical studies suggest could result in putative novel treatments for mood disorders. These include: (1) glycogen synthase kinase-3 (GSK-3) and protein kinase C (PKC), (2) the purinergic ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Neurotherapeutics
سال: 2010
ISSN: 1933-7213,1878-7479
DOI: 10.1016/j.nurt.2010.07.003